← Back to patent-cliff list
阿维巴坦钠/头孢他啶
Tier C — Watch / tradeAvibactam Sodium/Ceftazidime
艾尔建
Originator
2015
First approval
-
Expiry (public)
$0.64B ▲
Peak sales
化学药
Type
Targets：PBPs、Beta Lactamase
Brand：思福妥、Zavicefta、Avycaz
Indications (approved)：膀胱炎、胆囊炎、腹膜炎、腹腔感染、肝脓肿、脓毒病、肾盂肾炎、细菌性肺炎
Regional status
US
批准上市
2015-02-25
EU
批准上市
2016-06-23
China
批准上市
2019-05-21
Japan
批准上市
2024-06-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Avibactam Sodium/Ceftazidime?
Approved indications include: 膀胱炎, 胆囊炎, 腹膜炎, 腹腔感染, 肝脓肿, 脓毒病, 肾盂肾炎, 细菌性肺炎.
When does the Avibactam Sodium/Ceftazidime patent expire?
No public expiry year is available for Avibactam Sodium/Ceftazidime yet; this page updates once verified.
How do I get a quote for Avibactam Sodium/Ceftazidime intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24